$ELVR

Elevra Lithium Ltd (ASX:ELV) Binding Agreement Concluded with Mangrove Lithium

Elevra Lithium (ASX:ELV) has signed a binding 7-year spodumene supply agreement with Mangrove Lithium, extendable for another 7 years. The deal secures long-term local supply for Elevra's Quebec operations at market-linked prices with downside protection. Mangrove's facility, pending financing, will avoid Elevra's ocean freight costs. Both companies are backed by Canada Growth Fund.

Original reporting
Published Aug 24, 2026, 2:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 2:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Elevra Lithium Ltd (ASX:ELV) Binding Agreement Concluded with Mangrove Lithium — source image
Decision brief

The 30-second read

$ELVRBullishMed
01

Why it matters

The deal provides Elevra with a stable revenue stream, price floor protection, and reduced logistics costs, likely supporting its valuation.

02

Market read

First‑report of a material supply contract that could positively affect Elevra's share price and the broader North American lithium sector.

03

What to watch

Financing risk for Mangrove's conversion plant and potential delays in FID could affect contract execution.

Relevance 7/10Novelty 7/10Timing: announced today

Background

Elevra Lithium (NASDAQ:ELVR) secured a seven‑year supply agreement with Mangrove Lithium for spodumene concentrate from its North American Lithium project in Quebec.

Company-level read

Ticker impact

$ELVRBullishHigh confidence
Context

Elevra Lithium announced a binding Spodumene Concentrate Supply Agreement with Mangrove Lithium, securing long‑term off‑take and price floor.

Expected impact

Potential upside as market price for spodumene may rise; floor price above cost supports margins.

Evidence & confidence

New multi‑year supply deal with volume up to 144,000 dmt and no price ceiling gives Elevra exposure to price upside and reduces freight costs.

Market effects

Strengthens North American lithium supply chain, may benefit other battery‑material producers.

Boosts Canadian lithium sector confidence with Canada Growth Fund backing.

Adds to global lithium supply security, could influence lithium pricing trends.

Counterpoint

If market spodumene prices fall, the floor may limit upside and the contract could become a cost drag.

Key entities

  • Elevra Lithium Ltd

    North American lithium producer listed on NASDAQ (ELVR).

  • Mangrove Lithium

    Private lithium refining technology firm developing a conversion facility in Eastern Canada.

Related articles

$ELVRMed

Elevra Lithium Announces NAL Expansion Pre-Feasibility Study

Elevra Lithium (ASX:ELV; NASDAQ:ELVR) announced a Pre-Feasibility Study for its North American Lithium (NAL) expansion in Québec. The study projects increased annual spodumene concentrate production to 373ktpa, reduced unit costs, and a post-tax NPV of C$3,218M. The expansion is fully funded with C$366M in initial CAPEX and will be delivered in three stages, starting mid-2027.

$ELVRMed

Elevra Lithium Ltd (ASX:ELV) Corporate Presentation - Outlines Growth Strategy for North American Lithium Platform

Elevra Lithium Ltd (ASX:ELV) outlined its growth strategy for North American Lithium (NAL) in Quebec, targeting 373,000 tonnes of spodumene concentrate annually. FY26 production was 197,967 tonnes, with revenue of US$202 million. The company plans a three-stage expansion, with initial capital expenditure of US$271 million. FY27 production guidance is 198,000 to 210,000 tonnes.

$ELVRMed

Elevra Lithium Ltd (ASX:ELV) NAL Expansion Pre-Feasibility Study

Elevra Lithium (ASX:ELV, NASDAQ:ELVR) announced a Pre-Feasibility Study for its North American Lithium (NAL) expansion, targeting increased spodumene production and reduced costs. The project, fully funded at C$366M, aims to boost annual output to 373ktpa by mid-2029, with a post-tax NPV of C$3.218B. The expansion is expected to reduce LOM C1 costs to C$851/t post-expansion, according to the company.

$ELVRMed

Elevra Lithium H2 Earnings Call Highlights

Elevra Lithium reported cash of $255M at June 30, up from $47M a year earlier, with additional funding from convertible notes. NAL produced 198,000 tonnes of spodumene concentrate, down 3% YoY. Expansion plans include increasing milling capacity to 6,500 tonnes per day, with stage one expected by mid-2027. Fiscal 2027 guidance includes production of 198,000-210,000 tonnes and unit costs of $880-$950 per tonne.

$ELVRMed

Elevra Lithium Completes Binding Supply Agreement with Mangrove Lithium

Elevra Lithium (ASX:ELV, NASDAQ:ELVR) finalized a binding supply agreement with Mangrove Lithium for long-term spodumene concentrate supply from its North American Lithium facility in Québec. The deal follows a previous MoU and includes a price floor above production costs and no price ceiling. Elevra aims to avoid seaborne freight costs by supplying a local customer.